Clinical Trial Update: Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection [Phase 2]

View source ↗

Summary

Phase 2 study assessing pharmacokinetics, safety, and efficacy of SOF/VEL/VOX fixed-dose combination in adolescents and children with chronic hepatitis C; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination (SOF/VEL/VOX FDC)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: TERMINATED | Results posted: 2020-08-31